Cells from cancerous tumors can spread, or metastasize, throughout the body. Researchers have long sought to understand what determines where those cells will go and thrive in order to more ...

“Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint ...

Survivors of non-small cell lung cancer are at risk for both second primary lung cancers as well as non-lung secondary ...

Almost three-fourths of patients with biochemically recurrent prostate cancer remained metastasis free at 5 years following ...

Preclinical study findings point to new possibilities for strategies for treating metastatic TNBC patients for whom there are no specific therapies.

The FDA is reviewing zanzalintinib combined with atezolizumab for metastatic colorectal cancer, with a PDUFA target date of December 3, 2026. The STELLAR-303 trial showed significant overall survival ...

Rintatolimod (Ampligen) combined with durvalumab (Imfinzi) has continued to exhibit encouraging efficacy, safety, and ...

Low-dose aspirin may limit cancer metastasis by inhibiting platelet activation and enhancing T-cell immunity, supporting biomarker guided use while balancing bleeding risk overall.

New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from ...